SanofiSynthlabo News

A mother who has five children with birth defects she believes were caused by an anti-epilepsy drug has begun an online campaign to warn the public against the risks.

As a preview to the Biosimilar Drug Development World Europe 2012 conference we asked one of the key speakers Prof Heinz Haenel, Diabetes Division R+D Projects at Sanofi Aventis his thoughts on the current state of the industry.

Just three months before the world's second-best-selling drug gets U.S. generic competition, a generics company has paid nearly $445 million to finally end a decade-long, twist-filled patent infringement battle with two heavyweight drugmakers over blood thinner Plavix.

Sanofi's fourth quarter income of Genzyme and emerging markets offsets the death of patents and the effect of European Union rigor.

Sanofi and Bristol-Myers Squibb Company announced today that Apotex has made payment in the amount of $442,209,362 to Sanofi and Bristol-Myers Squibb to satisfy the damages ruling of the Plavix patent infringement case against Apotex.

Clarification of Conflict of Interest Disclosures in: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes Clarification of Conflict of Interest Disclosures: In the Editorial entitled "Hospitalizations for Heart Failure in the United States-A Sign of Hope," published in the October 19, 2011, issue of JAMA , and in ... (more)

The Food and Drug Administration on Tuesday approved Sanofi-Topaz's topical head lice treatment, which will be marketed under the brand name Sklice, for patients 6 month of age and older.

Sanofi-Aventis was downgraded by investment analysts at Goldman Sachs from a "neutral" rating to a "sell" rating in a note issued to investors on Wednesday.

In the past year there's been an uptick in big pharmaceutical companies' encouragement of innovation that leverages technology, open data and -- wait for it -- social media.

Suburban Propane Partners LP : Jim Cramer ranked this stock a Sell . The stock closed at $45.13, its 52-week high is $58.49, and its 52-week low is $40.25. Sanofi-Aventis : Jim Cramer ranked this stock a Buy .

The company provides medicines for the treatment of patients in several therapeutic areas, such as cardiovascular disease, thrombotic diseases, metabolic disorders, oncology, disorders of the central nervous system, internal medicine and vaccines.

CAMBRIDGE, Mass.-- --Jan 18, 2012 - Genzyme , a Sanofi company , announced today that the European Medicines Agency has approved its manufacturing plant in Framingham, Mass., for the production of Fabrazyme .

Sanofi-Aventis was downgraded by investment analysts at Bank of America to a "neutral" rating in a note issued to investors on Wednesday.

"You go on board! Is that clear? Do you hear me?" the Coast Guard officer shouted as the captain of... TRENTON - A former research chemist with global pharmaceutical company sanofi-aventis admitted on Tuesday to stealing sanofi-aventis trade secrets and making them available for sale through a U.S. subsidiary of a Chinese chemical company in China, ... (more)

A former research chemist in the New Jersey office of Sanofi-Aventis has pleaded guilty to one count of stealing trade secrets from her former employer.

Dr. Dhir will spearhead the national expansion of New Century Health's specialty care management services focused on oncology and cardiology.